Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 8;5(11):e1002.
doi: 10.1097/CCE.0000000000001002. eCollection 2023 Nov.

Molecular Adsorbent Recirculating System for Acute Liver Failure in a New Pediatric-Based Extracorporeal Liver Support Program

David R Baker  1 , Helen Mac  2 , Benjamin Steinman  3 , Sara H Soshnick  1 , Shalom Z Frager  4 , Beatrice Goilav  3 , Debora Kogan-Liberman  5 , Nadia Ovchinsky  5 , Mark Shlomovich  1
Affiliations

Molecular Adsorbent Recirculating System for Acute Liver Failure in a New Pediatric-Based Extracorporeal Liver Support Program

David R Baker et al. Crit Care Explor. .

Abstract

Importance: Acute liver failure (ALF) carries significant morbidity and mortality, for both pediatric and adult patients. Albumin dialysis via the molecular adsorbent recirculating system (MARS) is a form of extracorporeal liver support (ELS) that can reduce hepatic encephalopathy (HE), a main driver of mortality in ALF. However, data on MARS and its benefit on mortality have been inconsistent.

Objectives: We sought to report our experiences and patient outcomes from the first 2 years of operation of a new ELS program, within an established pediatric liver transplantation center.

Design setting and participants: Retrospective review of outcomes in pediatric and adult patients treated with MARS therapy for ALF, from 2021 to 2022.

Main outcomes and measures: Outcomes included reduction in HE and biochemical markers of ALF after MARS therapy, survival, and transplant-free survival. Comparisons were made via Wilcoxon signed-rank test.

Results: Five pediatric and two adult patients underwent MARS for ALF. Ages ranged from 2 to 29 years. Overall, 21 MARS runs were performed (median 3 runs per patient, 12.4 hr per run [interquartile range, IQR 10.1-17]). Overall survival was 85.7%, and transplant-free survival was 71.4%. There was a statistically significant reduction in HE score with MARS therapy (median 3 [IQR 3-4] to 1 [IQR 0-1], p = 0.03), and in ALF biomarkers including ammonia (256 µL/dL [195-265] to 75 µL/dL [58-101], p = 0.02), aspartate aminotransferase (6,362 U/L [920-8,305] to 212 U/L [72-431], p = 0.02), alanine aminotransferase (8,362 U/L [3,866-9,189] to 953 U/L [437-1,351], p = 0.02), and international normalized ratio (4.5 [3.3-6.7] to 1.3 [1.2-1.4], p = 0.02).

Conclusions and relevance: MARS therapy for ALF was well tolerated by both pediatric and adult patients, and resulted in significant improvement in clinical and biochemical parameters. We demonstrated encouraging overall and transplant-free survival, suggesting that early initiation of MARS with relatively long and frequent cycle times may be of significant benefit to ALF patients, and is worthy of additional study in larger cohorts.

Keywords: adult; extracorporeal circulation; hepatic encephalopathy; liver failure; liver transplantation; pediatric.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Change in biochemical and clinical parameters (group medians). Asterisks denote statistical significance. AST = aspartate aminotransferase, ALT = alanine aminotransferase, INR = international normalized ratio, MARS = molecular adsorbent recirculating system.
Figure 2.
Figure 2.
Change in hepatic encephalopathy (HE) (group median). Asterisk denotes statistical significance. MARS = molecular adsorbent recirculating system.
See this image and copyright information in PMC

References

    1. Lutfi R, Abulebda K, Nitu, Mara E, et al. : Intensive care management of pediatric acute liver failure. J Pediatr Gastroenterol Nutr 2017; 64:660–670 - PubMed
    1. Reuben A, Tillman H, Fontana RJ, et al. : Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med 2016; 164:724–732 - PMC - PubMed
    1. Ng VL, Li R, Loomes KM, et al. ; Pediatric Acute Liver Failure Study Group (PALFSG): Outcomes of children with and without hepatic encephalopathy from the pediatric acute liver failure study group. J Pediatr Gastroenterol Nutr 2016; 63:357–364 - PMC - PubMed
    1. García Martínez JJ, Bendjelid K: Artificial liver support systems: What is new over the last decade? Ann. Intensive Care 2018; 8:109. - PMC - PubMed
    1. Saliba F, Bañares R, Larsen FS, et al. : Artificial liver support in patients with liver failure: A modified DELPHI consensus of international experts. Intensive Care Med 2022; 48:1352–1367 - PubMed